Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Get coverage of the latest pharmaceutical business developments, and historical metrics on financing, licensing, partnership, and acquisition.
Our trusted Pharma Intelligence brands
Citeline
27 Jun 2022
Following on from our review of trends in the current pharmaceutical R&D pipeline, this supplement takes a look at the industry’s success stories of 2021 – the drugs which were launched onto the market for the first time during the year.
Citeline
27 Jun 2022
Take a look at the evolution of pharma R&D and in this article, examine the state of play at the start of 2022.
Citeline
27 Jun 2022
As the COVID-19 pandemic stretched through a second year, its impacts continued to reshape the clinical trials landscape.
Topic Clinical Trials
Citeline
27 Jun 2022
As the world begins its transition into a post-pandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects that COVID-19 has brought.
Topic Clinical Trials
Biomedtracker
By Dominique Fontanilla 20 Jun 2022
Understand important upcoming milestones that will impact the likelihood of drug approval or future sales potential for key therapies during a free webinar from Informa Pharma Intelligence, "Q4 Outlook Webinar - Key Catalysts and their Impact on Pharma Markets".
Datamonitor Healthcare
By Amanda Micklus 20 Jun 2022
As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.
Topic Cell & Gene Therapy
17 Jun 2022
As we continue to navigate unprecedented times, the pharma industry in the Asia Pacific region has been persistently moving forward with clinical trial advancements.
Meddevicetracker
17 Jun 2022
The webinar will provide a thought leadership perspective on the key challenges and trends in the emerging Robotic Surgery market.
Ian Lloyd 17 Jun 2022
Authored for the last 25 years by Ian Lloyd, Senior Director of Pharmaprojects and Data Integration, this vital resource uses a music motif to turn up the volume on the evolution of trends in pharmaceutical R&D. Lloyd assesses industry trends by examining the pipeline by company, therapeutic area, disease, target, and drug type.
Laura Runkel 17 Jun 2022
For a deeper look into the data behind last year’s completed clinical trials and the trends driving them, Listen to the Completed Clinical Trials 2017: Status Quo or No?
Pink Sheet
By Michael McCaughan 16 Jun 2022
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
Topic US Election 2020
Medtech Insight
By Sue Darcey 16 Jun 2022
Out of 31 US House incumbents supported by high amounts of medtech industry political action committee (PAC) dollars, only one – Chrissy Houlahan of Pennsylvania – lost in last week’s election.
Datamonitor Healthcare
By Louisa Joseph 16 Jun 2022
Join subject-matter experts from Datamonitor Healthcare as they use data and their industry experience to examine the challenges and opportunities brought about by recent global trends in market access. Learn how to navigate this complex terrain, as increasingly restrictive pricing and reimbursement policies are having an adverse effect on sales of launched and pipeline products across many global markets.
Topic Reimbursement
Pink Sheet
By Brian Yang 16 Jun 2022
Given the ongoing election challenges in the US, China has yet to officially congratulate Joe Biden as the next US president, although many world leaders are already hailing a reset in US foreign policy. Many are wondering if this and other moves indicate a quiet internal shift for China's high tech and life sciences sectors, just days after Beijing concluded a high-level plenary meeting outlining its priorities for the next five years.
Topic US Election 2020 China
Citeline Connect
16 Jun 2022
Accelerate study startup, drive engagement, and enable community and communication surrounding your clinical trials with Citeline Connect, the only end-to-end platform supporting all aspects of clinical trial recruitment.
Scrip
29 Jun 2022
HBW Insight
29 Jun 2022
Scrip
29 Jun 2022
Pink Sheet
29 Jun 2022
Pink Sheet
29 Jun 2022
Pink Sheet
29 Jun 2022
Medtech Insight
29 Jun 2022
Generics Bulletin
29 Jun 2022
Scrip
29 Jun 2022
Generics Bulletin
29 Jun 2022
Pink Sheet
29 Jun 2022
Pink Sheet
29 Jun 2022
HBW Insight
29 Jun 2022
HBW Insight
29 Jun 2022
Scrip
29 Jun 2022
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Key benefits:
12 Jul 2022 , 11:00
Webinar
20 Jul 2022 , 11:00
Webinar
28 Sep 2022 , 10:00
Webinar
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
